Abstract
The ErbB/HER pathway and epithelial mesenchymal transition (EMT) play important roles in tumor invasion and metastasis of breast cancer. Recently, it has been reported that EMT is also involved in the resistance to chemotherapy. This review highlights the biological role of HoxB9 and BTG2 in the development of breast cancer. Overexpression of HoxB9 and loss of BTG2 promote tumor growth and metastasis of breast cancer through activation of the ErbBR pathway and EMT. The expression rates of these genes might serve as useful biomarkers in the treatment of patients with breast cancer.
